Contents
43 Changing clinical trial feasibility SGS
Data management 45 Data is king
Courtney Soulsby, global director, healthcare sector at British Standards Institution (BSI) to find out how pharma companies can leverage serialisation to extract business value.
Outsourcing 29 Trial and error
Covid-19 transformed clinical trials practically overnight, with remote testing and quicker approvals suddenly becoming a reality the world over. These shifts aren’t hard to understand. Eager to defeat the pandemic as quickly as possible, researchers were happy to embrace change for financial and efficiency reasons. But with the pandemic finally passing into history, can we expect the revolutions of 2020 to
transform clinical trials over the long term? Andrea Valentino talks to Professor Kenneth Getz, at the Tufts Center for the Study of Drug Development, to learn more.
32 The case for trial diversity Lionbridge
33 Next generation clinical data management Exom Group
35 Rescue clinical trials Lumis
38 Measurable success Cerba Research
45 Clinical Trials Insight /
www.worldpharmaceuticals.net
41 Reduce monitoring costs ProofPilot
26
The advent of dedicated software has made it easier to keep track of the large volume of information involved in running a clinical trial. Yet the multiplicity of requirements and stakeholders means there are still challenges, not least of integration. Kim Thomas talks to Erin Pennington, director with the Huron Consulting Group, and Raymond Nomizu, CEO of start-up Clinical Research IO, to discover how research sites can maximise the benefits of their software investments.
Packaging
48 Read the small print The labels on drug packaging are one of the main drug/patient interfaces in a clinical trial, especially one that is conducted remotely. Despite this, confusion involving packaging and labelling on investigational drugs is frequently implicated in medication errors. David Callaghan speaks to pharmacy research coordinator at the Centre Hospitalier Universitaire (CHU) Sainte-Justine, Cynthia Tanguay and Matthew Grissinger, director of education at the Institute for Safe Medical Practices (ISMP) in the US, to find out how organisers can reduce the incidence of medication error in trials.
48 5
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
